Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Setmelanotide for ROHHAD syndrome
NL-OMON60125Phase 2Recruiting
- Sponsor
- University Medical Center Utrecht
- Start
- Apr 2025
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of setmelanotide in Rapid-onset obesity with hypothalamic dysfunction, hypoventilation, and autonomic dysregulation (ROHHAD), sponsored by University Medical Center Utrecht. Primary endpoint: Change in overall scores for signs and symptoms of hypothalamic dysfunction at 52 weeks. Started Apr 2025; status: recruiting.
02
Drugs
setmelanotide
03
Conditions
Rapid-onset obesity with hypothalamic dysfunction, hypoventilation, and autonomic dysregulation (ROHHAD)
Beyond the preview
Go deeper on NL-OMON60125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60125.